# US 2008/0188504 A1 · Process for Preparing Pure Amorphous Rosuvastatin Calcuim

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188504 A1
- Document ID: US20080188504A1
- Status: Published application
- Kind: A1
- Application number: 11/916,599
- Filed: 2006-06-22
- Published: 2008-08-07
- Earliest claimed: 2005-06-24
- Assignees: Lek D.D
- Inventors: Zendko Casar; Marko Zlicar
- Web page: https://patentgrep.com/patent/US20080188504A1

## CPC

- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A new process for preparing pure amorphous rosuvastatin calcium, substantially free of impurities, is disclosed. A process comprising hydrolysing a C1 to C5 alkyl ester of rosuvastatin, preferably methyl rosuvastatin or tert-butyl rosuvastatin, with a base, e.g. sodium hydroxide, in the presence of an aprotic solvent, preferably tetrahydrofuran and N,N-dimethyl acetamide, or in the presence of a mixture of an aprotic solvent and water, to obtain a solution of rosuvastatin salt, which may be converted to another rosuvastatin salt using another cation, e.g. with calcium cation to obtain rosuvastatin calcium. Rosuvastatin amine salts may be obtained as well. In another preferred aspect of the invention rosuvastatin free acid may be converted to various rosuvastatin salts, e.g. to rosuvastain calcium, rosuvastatin sodium or various rosuvastatin amine salts, including rosuvastatin solvates, e.g. rosuvastatin calcium hydrate. Rosuvastatin calcium is useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.

## Claims

### Claim 1

A process for producing pure amorphous rosuvastatin calcium which comprises:
a) hydrolysing a C1 to C5 alkyl ester of rosuvastatin with a base in the presence of an aprotic solvent or with a base in the presence of a mixture of an aprotic solvent and water, to obtain a solution of rosuvastatin salt,
b) converting thus obtained rosuvastatin salt with a source of calcium to obtain rosuvastatin calcium,
c) isolating the amorphous rosuvastatin calcium.

### Claim 2 (depends on 1)

The process according to claim 1, wherein C1 to C5 alkyl ester of rosuvastatin is tert-butyl rosuvastatin.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the aprotic solvent is tetrahydrofuran.

### Claim 4 (depends on 3)

The process according to claim 3, wherein the ratio of tetrahydrofuran and water is from 5:1 to 1:5 by volume.

### Claim 5 (depends on 3)

The process according claim 3, wherein the ratio of tetrahydrofuran and water is from 4:1 to 1:3 by volume.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the base is sodium hydroxide.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the source of calcium is selected from the group consisting of calcium chloride, calcium nitrate, calcium hydroxide and calcium salt of C1-C20 alkanoic acid.

### Claim 8 (depends on 7)

The process according to claim 7, wherein the calcium salt of C1-C20 alkanoic acid is selected from the group consisting of calcium palmitate, calcium pivalate and calcium acetate.

### Claim 9 (depends on 1)

The process according to claim 1, wherein rosuvastatin calcium is isolated in a solid form.

### Claim 10 (depends on 1)

The process for producing amorphous rosuvastatin calcium according to claim 1, wherein the mixture prepared in step a) is treated by ultraturrax.

### Claim 11 (depends on 1)

The process according to claim 1, wherein the alkyl of the C1 to C5 alkyl ester of rosuvastatin denotes methyl, ethyl, n-proply, iso-propyl, n-butyl, iso-butyl, tert-butyl, amyl, or tert-amyl.

### Claim 12

A process for producing amorphous rosuvastatin calcium, which includes the steps of:
a) hydrolyzing a C1 to C5 alkyl ester of rosuvastatin with a base in an aprotic solvent;
b) removing the aprotic solvent to obtain a residue;
c) combining the residue with water to obtain an aqueous solution of rosuvastatin salt of a base;
d) optionally washing the obtained aqueous solution with a water immiscible organic solvent;
e) optionally removing the organic solvent;
f) adding a source of calcium to the resulted solution to precipitate rosuvastatin calcium; and
g) isolating the amorphous rosuvastatin calcium salt.

### Claim 13 (depends on 12)

The process according to claim 12, wherein the aprotic solvent is N,N-dimethylacetamide, optionally in combination with an ether.

### Claim 14 (depends on 13)

The process according to claim 13, wherein the ratio of N,N-dimethylacetamide and diethyl ether is from 1:1 to 3:1 by volume.

### Claim 15 (depends on 12)

The process for producing amorphous rosuvastatin calcium according to claim 12, wherein the mixture prepared in step a) is treated by ultraturrax.

### Claim 16 (depends on 12)

The process according to claim 12, wherein the alkyl of the C1 to C5 alkyl ester of rosuvastatin denotes methyl, ethyl, n-proply, iso-propyl, n-butyl, iso-butyl, tert-butyl, amyl, or tert-amyl.

### Claim 17 (depends on 12)

The process according to claim 12 wherein the water immiscible organic solvent is ethyl acetate.

### Claim 18

A process for producing rosuvastatin free acid, which includes the steps of:
a) hydrolysing a C1 to C5 alkyl ester of rosuvastatin with a base in an aprotic solvent,
b) removing excess of organic aprotic solvent;
c) optionally diluting water poor solution with additional water,
d) optionally washing thus obtained aqueous solution of rosuvastatin salt of a base with a water immiscible organic solvent
e) acidifying aqueous solution of rosuvastatin salt of a base,
f) extracting the resulted rosuvastatin acid with the water immiscible organic solvent,
g) removing the water immiscible organic solvent from the resulted extract to obtain isolated rosuvastatin free acid.

### Claim 19 (depends on 18)

The process according to claim 18, wherein C1 to C5 alkyl ester of rosuvastatin is methyl rosuvastatin.

### Claim 20 (depends on 18)

The process according to claim 18, wherein C1 to C5 alkyl ester of rosuvastatin is tert-butyl rosuvastatin.

### Claim 21 (depends on 18)

A process according to claim 18, wherein the alkyl of the C, to C5 alkyl ester of rosuvastatin denotes methyl, ethyl, n-proply, iso-propyl, n-butyl, iso-butyl, tert-butyl, amyl, or tert-amyl.

### Claim 22 (depends on 10)

The process according to claim 10 wherein the water immiscible solvent is ethyl acetate.

### Claim 23 (depends on 18)

The process according to claim 18 e), wherein hydrochloric acid is used for acidifying the aqueous solution.

### Claim 24

A process for producing rosuvastatin salts, wherein isolated rosuvastatin free acid is contacting with cation source in an organic solvent.

### Claim 25 (depends on 24)

The process for producing rosuvastatin calcium according to claim 24 wherein isolated rosuvastatin free acid is contacting with calcium source in an organic solvent.

### Claim 26 (depends on 24)

The process for producing rosuvastatin calcium according to claim 24, wherein an organic solvent is selected from the group consisting of C2 to C4 alkyl acetate esters.

### Claim 27 (depends on 24)

The process for producing rosuvastatin calcium according to claim 24, wherein isolated rosuvastatin free acid has a water content less than 0.1% by weight.

### Claim 28 (depends on 25)

The process for preparing rosuvastatin calcium according to claim 25, wherein the calcium source is calcium 2-ethylhexanoate.

### Claim 29 (depends on 25)

The process for preparing rosuvastatin calcium monohydrate according to claim 25, wherein isolated rosuvastatin free acid is contacting with calcium source in a mixture of acetone and water.

### Claim 30 (depends on 1)

Amorphous rosuvastatin calcium in solid state, prepared according to claim 1, having a purity of more than 99.8% as measured by area percentage using HPLC.

### Claim 31 (depends on 1)

Amorphous rosuvastatin calcium in solid state, prepared according to claim 1 having a purity of more than 99.9% as measured by area percentage using HPLC.

### Claim 32

Substantially anhydrous rosuvastatin calcium having water content less than 0.1% by weight.

### Claim 33 (depends on 1)

A pharmaceutical formulation for administration to a mammal in need of a reduction in blood cholesterol level comprising rosuvastatin calcium prepared according to claim 1.

### Claim 34 (depends on 33)

A method of treating a mammal in need of a reduction in blood cholesterol level comprising the step of administering the pharmaceutical formulation of claim 33 to the mammal in need thereof.
